|Mr. Christopher Schelling||Founder, Pres, CEO & Director||436k||N/A||1976|
|Mr. Harry S. Palmin||COO, CFO & Principal Accounting Officer||382.4k||N/A||1970|
|Mr. John Michael Klopp||Chief Technical Officer||N/A||N/A||1975|
|Mr. Donald R. Joseph||Chief Legal Officer & Sec.||N/A||N/A||1954|
|Ms. Jeannie Kim||VP of Corp. Devel.||N/A||N/A||N/A|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.
Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.